Technologieangebote

cPLA2–Inhibitor (stoPLA) – New compounds for the topical treatment of skin inflammation

Novel group of nonsteroidal anti-inflammatory drugs: The new class of heteroaryl-substituted acetone derivatives inhibits effectively the cytosolic phospholipase A2 (cPLA2).

The compounds interact with the synthesis of prosta-glandins and leukotrienes and reduce inflammatory processes. The substances have an excellent solubility profile. The heteroaryl-substituted acetone derivatives provide the platform for the development of new pharmaceutical products for the treatment of inflammatory diseases of the skin, such as psoriasis and atopic dermatitis.

Weitere Informationen: PDF

PROvendis GmbH
Tel.: +49 (0)208/94105 10

Ansprechpartner
Dipl.-Ing. Alfred Schillert

Kommentare (0)

Schreiben Sie einen Kommentar